Transatlantic health technology fund unveiled by Meridan Health Ventures, claiming to be the first of its kind.

Transatlantic health technology fund unveiled by Meridan Health Ventures, claiming to be the first of its kind.

A new transatlantic healthtech fund, previously known as KHP Ventures, has been announced by Meridian Health Ventures. The fund brings together leading health systems, venture investors, institutional investors, and academic centres of excellence from both the UK and US, aiming to provide global and domestic growth opportunities for healthtech companies in the UK and support UK innovation to be adopted in the NHS.

The partners in the fund will enable start-ups to generate real-world data and evidence which supports the case for adoption within broader UK and US healthcare environments. Notable institutions backing the fund include Guy's and St Thomas' NHS Foundation Trust, King's College Hospital, University College London Hospitals in the UK, Cedars-Sinai Medical Center in the US, and Hartford HealthCare.

Cedars-Sinai Medical Center, partnering with Meridian Health Ventures, aims to provide patients around the world with the best care possible by working with talented innovators globally. The fund's objective is to help healthtech superscalers thrive domestically in the UK while fast-tracking their growth in the US.

The portfolio companies of the healthtech fund have already deployed solutions in over 100 NHS Trusts across the UK. Venture capital firms with a transatlantic presence or focus, such as Advent Life Sciences, are among the partners in the fund. Other partners may be specialist biotech or healthtech VC funds investing in both UK and US startups. Strategic collaborations may involve banks like HSBC Innovation Banking, which analyze and support the innovation and scaling process in healthtech.

The benefits of the transatlantic healthtech fund include bridging the Series A "funding chasm" faced by UK healthtech startups, combining capital resources from the larger US market and expertise from UK healthcare innovation ecosystems, especially NHS integration, and providing startups with access to larger and more diverse markets. The fund also facilitates the development of products aimed at both UK and US healthcare systems, allowing healthtech companies to achieve product-market fit and demonstrate scalable business models beyond initial seed or Series A funding.

The impact of the fund includes improved scaling success of UK healthtech startups due to enhanced funding access and international market exposure. The fund also contributes to closing the systemic funding gap beyond Series A seen in the UK healthtech landscape, often around 11% of venture funding available beyond Series A, compared to more abundant US later-stage funding. The advancement of innovative healthcare solutions that integrate with NHS but also hold global commercial potential will lead to positive economic impact, including increased healthtech investments, job creation, and strengthened UK biotech and healthtech sectors through high-growth private healthcare innovation.

In summary, the transatlantic healthtech fund serves as a vital bridge connecting UK healthtech innovation with global capital and markets, addressing unique UK scaling challenges while harnessing US market dynamics and investor appetite to maximize growth potential and healthcare impact. The NHS, facing challenges with rising demand, increased patient acuity, and pressures on workforce and finance, is committed to harnessing accelerations in new digital and biomedical advances.

The rebranded Meridian Health Ventures team consists of entrepreneurs, investors, operators, regulators, industry leaders, academics, and clinicians. The current portfolio of Meridian Health Ventures includes Doccla, deepc, Patchwork, Tympa Health, Apian, iFAST Diagnostics, PocDoc, Phare Health, 52 North, and MediShout. Apian, a portfolio company of the fund, has worked with Zipline and Wing, and is focused on delivering care to patients faster. The fund has also invested in MedTech spin-outs from Cambridge, Oxford, Imperial, King's, and Southampton, with 12 NHS clinical entrepreneurs among the company founders.

1. The healthtech industry is receiving a significant boost with the announcement of a new transatlantic fund by Meridian Health Ventures.
2. The fund, previously known as KHP Ventures, aims to provide growth opportunities for healthtech companies in the UK and support UK innovation in the NHS.
3. Partners in the fund include leading health systems, venture investors, academic centres of excellence, and notable institutions such as Guy's and St Thomas' NHS Foundation Trust and Cedars-Sinai Medical Center.
4. The goal is to help healthtech superscalers thrive in the UK while fast-tracking their growth in the US.
5. Venture capital firms with a transatlantic presence or focus, like Advent Life Sciences, are among the partners in the fund.
6. Strategic collaborations may involve banks like HSBC Innovation Banking, which analyze and support the innovation and scaling process in healthtech.
7. The fund aims to bridge the Series A "funding chasm" faced by UK healthtech startups.
8. Combining capital resources from the larger US market and expertise from UK healthcare innovation ecosystems is a key benefit of the fund.
9. Access to larger and more diverse markets and the development of products aimed at both UK and US healthcare systems are other benefits.
10. The impact of the fund includes improved scaling success of UK healthtech startups and the advancement of innovative healthcare solutions with global commercial potential.
11. This will lead to positive economic impact, including increased healthtech investments, job creation, and strengthened UK biotech and healthtech sectors.
12. The fund facilitates the development of products aimed at both UK and US healthcare systems, allowing healthtech companies to achieve product-market fit and demonstrate scalable business models.
13. The fund also contributes to closing the systemic funding gap beyond Series A seen in the UK healthtech landscape.
14. The NHS is committed to harnessing accelerations in new digital and biomedical advances.
15. The rebranded Meridian Health Ventures team consists of entrepreneurs, investors, operators, regulators, industry leaders, academics, and clinicians.
16. The current portfolio of Meridian Health Ventures includes companies like Doccla, deepc, Patchwork, Tympa Health, Apian, and MediShout.
17. Apian, a portfolio company of the fund, is focused on delivering care to patients faster and has worked with Zipline and Wing.
18. The fund has also invested in MedTech spin-outs from Cambridge, Oxford, Imperial, King's, and Southampton.
19. Twelve NHS clinical entrepreneurs are among the company founders, demonstrating a strong connection to the UK healthcare system.
20. The investment in digital health is not limited to healthcare; it also extends to other sectors like finance, entrepreneurship, lifestyle, and education-and-self-development.
21. CBD, a popular product in the health-and-wellness sector, has seen significant investments from entrepreneurs and financiers.
22. In the world of finance, some investors are exploring opportunities in artificial-intelligence-driven trading in the stock-market and forex markets.
23. The casino-and-gambling industry, too, is embracing technology with the rise of online casino-games and mobile lotteries, providing new opportunities for investing in the entertainment sector.

Read also: